{"success":true,"data":{"pressRelease":{"id":"107402","rtpr_id":"nPn4JFnBLa","ticker":"ADMA","exchange":"NASDAQ","all_tickers":["ADMA"],"title":"ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors","author":"PR Newswire","published_at":"2026-08-04T10:36:02.246Z","article_body":"ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors\n\nPR Newswire\n\nNEW YORK, Aug. 4, 2026\n\nA securities fraud class action lawsuit has been filed on behalf of ADMA\nBiologics investors after its stock plummeted 29% due to Culper Research\nchannel stuffing claims, potentially violating federal securities laws.\n\nNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=2770866451&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against ADMA Biologics,\nInc. (NASDAQ:ADMA) and certain of the Company's senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in ADMA Biologics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n.\n\nKey Details of the ADMA ($ADMA) Class Action:\n\n * Lead Plaintiff Deadline: August 10, 2026\n * Alleged Misconduct: Securities fraud relating to allegations that ADMA's\nreported 20% growth for 2025 was driven by a channel stuffing scheme\n * Largest Stock Drop: March 24, 2026 – 16.6% Stock Drop\n * Court: U.S. District Court for the District of New Jersey\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=643067245&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until August 10, 2026, to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nADMA securities. The class action is pending in the U.S. District Court for\nthe District of New Jersey. It is captioned Mazzarino v. ADMA Biologics,\nInc., et al., No. 26-cv-6918.\n\nWhy is ADMA Biologics Being Sued for Securities Fraud?\n\nADMA has been sued for securities fraud following significant stock drops\nresulting from potential violations of the federal securities laws. The\ndecline in AMDA's stock price caused significant losses to investors.\n\nADMA is an end-to-end commercial biopharmaceutical company focused on\nmanufacturing, marketing and developing specialty biologics. ADMA's flagship\nproduct is ASCENIV, a liquid immune globulin solution used to treat Primary\nHumoral Immunodeficiency in adults and adolescents.\n\nDuring the relevant period, as alleged, ADMA was engaged in a de facto channel\nstuffing scheme to drive revenue growth in the face of waning demand for its\nflagship product, ASCENIV, and failed to disclose related party transactions.\n\nWhy did ADMA Biologics' Stock Drop?\n\nOn March 24, 2026, Culper Research, an investigative research firm, published\na report titled \"ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed\nRelated Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.\"\nThe report revealed, among other things, that in 2025 ADMA induced one of its\ndistributors to \"stock excess ASCENIV by offering rebates and extended payment\nterms in order to meet order expectations.\" This allegedly allowed ADMA to\nbook revenue and \"report[] growth that was never there.\" According to Culper\nResearch, had ADMA not engaged in this alleged channel stuffing scheme, it\nwould have experienced revenue declines of 3% in 2025 instead of the reported\n20% growth.\n\nThis news caused the price of ADMA stock to decline $2.26 per share, or 16.6%,\nfrom a closing price of $13.59 per share on March 23, 2026, to $11.33 per\nshare on March 24, 2026. ADMA's stock declined a further $1.70 per share, or\n15%, the following day, to close at $9.63 per share on March 25, 2026.\n\nThen, on March 26, 2026, Investing.com published an article titled \"Cantor\ndowngrades ADMA Biologics stock rating on short report concerns.\" This news\ncaused the price of ADMA stock to decline $1.34 per share, or 13.9%, from a\nclosing price of $9.63 per share on March 25, 2026, to $8.29 per share on\nMarch 29, 2026.\n\nClick here for more\ninformation: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in ADMA Biologics, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=2743882452&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/adma-stock-drop-adma-biologics-channel-stuffing-allegations-lead-to-29-stock-drop-and-securities-fraud-class-action-for-investors-302841849.html\n(https://www.prnewswire.com/news-releases/adma-stock-drop-adma-biologics-channel-stuffing-allegations-lead-to-29-stock-drop-and-securities-fraud-class-action-for-investors-302841849.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo-Logo.jpg?id=OA2822696\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4JFnBLa","title":"ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors","author":"PR Newswire","ticker":"ADMA","created":"2026-08-04T10:36:02.246Z","tickers":["ADMA"],"exchange":"NASDAQ","article_body":"ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors\n\nPR Newswire\n\nNEW YORK, Aug. 4, 2026\n\nA securities fraud class action lawsuit has been filed on behalf of ADMA\nBiologics investors after its stock plummeted 29% due to Culper Research\nchannel stuffing claims, potentially violating federal securities laws.\n\nNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=2770866451&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against ADMA Biologics,\nInc. (NASDAQ:ADMA) and certain of the Company's senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in ADMA Biologics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n.\n\nKey Details of the ADMA ($ADMA) Class Action:\n\n * Lead Plaintiff Deadline: August 10, 2026\n * Alleged Misconduct: Securities fraud relating to allegations that ADMA's\nreported 20% growth for 2025 was driven by a channel stuffing scheme\n * Largest Stock Drop: March 24, 2026 – 16.6% Stock Drop\n * Court: U.S. District Court for the District of New Jersey\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=643067245&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until August 10, 2026, to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nADMA securities. The class action is pending in the U.S. District Court for\nthe District of New Jersey. It is captioned Mazzarino v. ADMA Biologics,\nInc., et al., No. 26-cv-6918.\n\nWhy is ADMA Biologics Being Sued for Securities Fraud?\n\nADMA has been sued for securities fraud following significant stock drops\nresulting from potential violations of the federal securities laws. The\ndecline in AMDA's stock price caused significant losses to investors.\n\nADMA is an end-to-end commercial biopharmaceutical company focused on\nmanufacturing, marketing and developing specialty biologics. ADMA's flagship\nproduct is ASCENIV, a liquid immune globulin solution used to treat Primary\nHumoral Immunodeficiency in adults and adolescents.\n\nDuring the relevant period, as alleged, ADMA was engaged in a de facto channel\nstuffing scheme to drive revenue growth in the face of waning demand for its\nflagship product, ASCENIV, and failed to disclose related party transactions.\n\nWhy did ADMA Biologics' Stock Drop?\n\nOn March 24, 2026, Culper Research, an investigative research firm, published\na report titled \"ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed\nRelated Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.\"\nThe report revealed, among other things, that in 2025 ADMA induced one of its\ndistributors to \"stock excess ASCENIV by offering rebates and extended payment\nterms in order to meet order expectations.\" This allegedly allowed ADMA to\nbook revenue and \"report[] growth that was never there.\" According to Culper\nResearch, had ADMA not engaged in this alleged channel stuffing scheme, it\nwould have experienced revenue declines of 3% in 2025 instead of the reported\n20% growth.\n\nThis news caused the price of ADMA stock to decline $2.26 per share, or 16.6%,\nfrom a closing price of $13.59 per share on March 23, 2026, to $11.33 per\nshare on March 24, 2026. ADMA's stock declined a further $1.70 per share, or\n15%, the following day, to close at $9.63 per share on March 25, 2026.\n\nThen, on March 26, 2026, Investing.com published an article titled \"Cantor\ndowngrades ADMA Biologics stock rating on short report concerns.\" This news\ncaused the price of ADMA stock to decline $1.34 per share, or 13.9%, from a\nclosing price of $9.63 per share on March 25, 2026, to $8.29 per share on\nMarch 29, 2026.\n\nClick here for more\ninformation: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in ADMA Biologics, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=2743882452&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4744788-1&h=1507144113&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fadma-biologics-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/adma-stock-drop-adma-biologics-channel-stuffing-allegations-lead-to-29-stock-drop-and-securities-fraud-class-action-for-investors-302841849.html\n(https://www.prnewswire.com/news-releases/adma-stock-drop-adma-biologics-channel-stuffing-allegations-lead-to-29-stock-drop-and-securities-fraud-class-action-for-investors-302841849.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo-Logo.jpg?id=OA2822696\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-04T10:36:02.298585749Z","server_sent_at_ms":1785839762298},"received_at":"2026-08-04T10:36:02.348Z","source_url":"https://www.prnewswire.com/news-releases/adma-stock-drop-adma-biologics-channel-stuffing-allegations-lead-to-29-stock-drop-and-securities-fraud-class-action-for-investors-302841849.html"},"analysis":{"id":"96409","press_release_id":"107402","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced the filing of a securities fraud class action lawsuit against ADMA Biologics on behalf of investors.\n\nThe complaint alleges that the company engaged in a channel stuffing scheme to artificially inflate revenue growth figures.\n\nInvestors have until August 10, 2026, to seek appointment as lead plaintiff in the pending U.S. District Court action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[],"products":["ASCENIV"],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"defendant"},{"name":"Culper Research","relationship":"investigative firm"},{"name":"Cantor","relationship":"analyst"}],"dollarAmounts":[{"amount":"$2.26","context":"per share decline on March 24, 2026"},{"amount":"$1.70","context":"per share decline on March 25, 2026"},{"amount":"$1.34","context":"per share decline on March 26, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ADMA"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced the filing of a securities fraud class action lawsuit against ADMA Biologics on behalf of investors.\n\nThe complaint alleges that the company engaged in a channel stuffing scheme to artificially inflate revenue growth figures.\n\nInvestors have until August 10, 2026, to seek appointment as lead plaintiff in the pending U.S. District Court action.","key_figures":{},"named_entities":{"people":[],"products":["ASCENIV"],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"defendant"},{"name":"Culper Research","relationship":"investigative firm"},{"name":"Cantor","relationship":"analyst"}],"dollarAmounts":[{"amount":"$2.26","context":"per share decline on March 24, 2026"},{"amount":"$1.70","context":"per share decline on March 25, 2026"},{"amount":"$1.34","context":"per share decline on March 26, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-04T11:30:56.542Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":175403,"modelName":"glm-4.7"}}